Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Garrelts, Alyssa, Malatestinic, William, Birt, Julie, Zhu, Baojin, Feely, Meghan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613184/
https://www.ncbi.nlm.nih.gov/pubmed/37752409
http://dx.doi.org/10.1007/s13555-023-01015-w
_version_ 1785128774601277440
author Blauvelt, Andrew
Garrelts, Alyssa
Malatestinic, William
Birt, Julie
Zhu, Baojin
Feely, Meghan
author_facet Blauvelt, Andrew
Garrelts, Alyssa
Malatestinic, William
Birt, Julie
Zhu, Baojin
Feely, Meghan
author_sort Blauvelt, Andrew
collection PubMed
description
format Online
Article
Text
id pubmed-10613184
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-106131842023-10-30 Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA Blauvelt, Andrew Garrelts, Alyssa Malatestinic, William Birt, Julie Zhu, Baojin Feely, Meghan Dermatol Ther (Heidelb) Letter Springer Healthcare 2023-09-26 /pmc/articles/PMC10613184/ /pubmed/37752409 http://dx.doi.org/10.1007/s13555-023-01015-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Letter
Blauvelt, Andrew
Garrelts, Alyssa
Malatestinic, William
Birt, Julie
Zhu, Baojin
Feely, Meghan
Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title_full Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title_fullStr Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title_full_unstemmed Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title_short Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title_sort letter to the editor: response to fitzgerald t et al. long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the usa
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613184/
https://www.ncbi.nlm.nih.gov/pubmed/37752409
http://dx.doi.org/10.1007/s13555-023-01015-w
work_keys_str_mv AT blauveltandrew lettertotheeditorresponsetofitzgeraldtetallongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa
AT garreltsalyssa lettertotheeditorresponsetofitzgeraldtetallongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa
AT malatestinicwilliam lettertotheeditorresponsetofitzgeraldtetallongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa
AT birtjulie lettertotheeditorresponsetofitzgeraldtetallongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa
AT zhubaojin lettertotheeditorresponsetofitzgeraldtetallongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa
AT feelymeghan lettertotheeditorresponsetofitzgeraldtetallongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa

Ejemplares similares